Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

Andrew S. Levey(Tufts Medical Center), Kerry Willis(National Kidney Foundation), Vlado Perkovic(New South Wales Department of Health), Hiddo J.L. Heerspink(University Medical Center Groningen), Morgan E. Grams(New York University), Dick de Zeeuw(University Medical Center Groningen), Adeera Levin(University of British Columbia), Josef Coresh(New York University), Edward F. Vonesh(Northwestern University), Lesley A. Inker(Tufts Medical Center), Hocine Tighiouart(Tufts University), Luxia Zhang(Peking University), Kai‐Uwe Eckardt(Friedrich-Alexander-Universität Erlangen-Nürnberg), Yingying Sang(Johns Hopkins University), Shoshana H. Ballew(New York University), Tom Manley(National Kidney Foundation), Kunihiro Matsushita(Johns Hopkins University), Ron T. Gansevoort(University Medical Center Groningen), Jian Ying(University of Utah), Tom Greene(University Medical Center Groningen)
American Journal of Kidney Diseases
August 28, 2019
Cited by 561


Related Papers